Value20202021202220232024TTMSelling/general/admin expenses9.51 M11.02 M12.21 M9.69 M4.13 M2.74 MResearch & development47.3 M55.71 M63.95 M41.04 M8.42 M—Operating income56.81 M66.72 M76.16 M49.26 M16.25 M2.78 MNon-Operating Income, Total3.21 M353 K1.37 M2.34 M493 K444 KInterest expense, net of interest capitalized3.92 M03.36 M5.3 M5 000—Non-Operating Income, excl. Interest Expenses-708 K0-1.99 M-2.94 M493 K444 KUnusual income/expense—353 K—-9 000-5 000—Pretax income56.1 M67.08 M74.17 M50.29 M16.73 M3.22 MEquity in earnings——————Taxes——————Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations60.02 M66.37 M77.53 M51.6 M15.75 M2.33 MDiscontinued operations——————Net income60.02 M66.37 M77.53 M51.6 M15.75 M2.33 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders60.02 M66.37 M77.53 M51.6 M15.75 M2.33 MBasic earnings per share (Basic EPS)——-562.5-300-38.576.25Diluted earnings per share (Diluted EPS)——-562.5-300-38.576.25Average basic shares outstanding——137.91 K172.08 K609.7 K13.73 MDiluted shares outstanding——137.91 K172.08 K609.7 K13.73 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)4.02 M2.2 M3.17 M2.02 M700 K114 K
Mustang Bio Inc
Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency.